Glenn Mattes joined the company in May 2018, bringing more than 30 years of business leadership, global therapeutics development expertise, and executive management experience to his role with the company.

In his capacity as Chief Executive Officer, Mr. Mattes, has oversight of the direction and strategy at TFF Pharmaceuticals, facilitating company activity in business development, marketing, investor relations, commercialization alliances and channels, and management support. He works to share the company’s vision and strategy with partners, investors and shareholders.

As Executive Chairman of Translational Sciences, Inc. the company consummated a global strategic collaboration in 2015 with Daiichi Sankyo for its lead cardiovascular asset. Prior to joining Translational Sciences, Mr. Mattes was CEO of Arno Therapeutics, a publicly traded company with a portfolio of development stage oncology therapeutic compounds, and a highly regarded group of founding investors.

From 2002 thru 2011 Mr. Mattes served as President of Tibotec Therapeutics, a Johnson & Johnson operating company, where he led, from inception, the organization responsible for the development, marketing, sales and business development of oncology and novel antiretroviral therapeutics. Tibotec’s revenues grew from zero to approximately $1 billion under Mr. Mattes’ leadership. During his Tibotec tenure, he led the successful launch of the first two Johnson & Johnson products launched into the HIV/AIDS market and presided over the growth of both Doxil and Procrit in the oncology therapeutic and supportive care categories.

From 1998 thru 2002 Mr. Mattes served as Vice President of Worldwide Commercial and Clinical Operations at Centocor Inc. He played a critical role in defining the company’s overall business direction as well as developing and implementing the strategy leading to the growth of ReoPro and the commercial launch of Remicade.
Prior to joining Centocor Mr. Mattes was at Rhône Poulenc Rorer, where he held positions of increasing responsibility, including President of RPR Canada and General Manager of U.S. pharmaceuticals. At Rhône Poulenc Rorer he built a market-leading asthma and allergy business with a focus on inhalation therapies. In addition, he was the General Manager of Advanced Therapeutics and Oncology, North America, and headed the successful launches of two blockbuster drugs, Taxotere and Lovenox.

In 2008 Mr. Mattes was honored with an appointment to the President’s Advisory Council on HIV/AIDS by President George W. Bush and the U.S. Secretary of Health and Human Services. In his service to the United States as a member of PACHA he was a key contributor to the committee responsible for counseling both the Bush and Obama administrations on domestic and global health and treatment issues.

Mr. Mattes serves on the Boards of Advantagene, Inc., Deck Therapeutics, Cornovus, Inc. and CannaMetrix. He is an advisor to the Gores Group and Clayton Foundation for Research, and served as an advisor to PTV Healthcare Capital. He is also an Operating Partner of Revival Healthcare.

Mr. Mattes received a Bachelor of Science degree from the City University of New York.